MACH7 TECHNOLOGIES LIMITED (M7T)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

M7T

M7T - MACH7 TECHNOLOGIES LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.95
Index:

Mach7 Technologies develops software platforms for the healthcare industry. It specialises in image management systems and patient data management. The company has been listed on the ASX since 2005.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.32

29 Aug
2025

-0.010

OPEN

$0.33

-3.03%

HIGH

$0.33

179,335

LOW

$0.31

TARGET
$0.81 153.1% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . IDX . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
M7T: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 2.6 - 2.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-2.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx33.8 M
Book Value Per Share xxxxxxxxxxxxxxx19.4
Net Operating Cash Flow xxxxxxxxxxxxxxx0.9 M
Net Profit Margin xxxxxxxxxxxxxxx-18.36 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-12.73 %
Return on Invested Capital xxxxxxxxxxxxxxx-12.47 %
Return on Assets xxxxxxxxxxxxxxx-9.04 %
Return on Equity xxxxxxxxxxxxxxx-12.73 %
Return on Total Capital xxxxxxxxxxxxxxx-16.87 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx0.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx4 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx23 M
Price To Book Value xxxxxxxxxxxxxxx1.70

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.7 M
Capex % of Sales xxxxxxxxxxxxxxx5.03 %
Cost of Goods Sold xxxxxxxxxxxxxxx36 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx7 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

28/08/2025

1

Buy

$0.81

153.13%

Mach7 Technologies’ FY25 result showed progress in recurring revenue and cost leverage, highlights Morgans, with revenue of $33.8m up 16% year-on-year but slightly below the broker’s $34.7m forecast.

Recurring revenue rose 20% to $25.3m, now 75% of group revenue and covering 80% of costs, point out the analysts, while adjusted earnings (EBITDA) narrowed to -$0.3m, close to breakeven.

The net loss incurred was -$6.2m against the broker’s forecast of -$4.8m, with operating cash flow (OCF) of $0.9m and a cash balance of $23.1m.

New logo wins remain limited, cautions Morgans, though client retention and expansion were strong. Strategic changes under the new CEO include resetting sales execution and strengthening customer support.

Morgans lowers its target price to 81c from $1.37 and retains a Buy rating. The broker expects recurring revenue momentum and new contract wins to drive operating leverage, though progress will take time.

FORECAST
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -2.20 cents.
Morgans forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.50 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

01/05/2025

1

Overweight

$0.85

165.63%

Mach7 Technologies reported a $24.4m annual recurring revenue (ARR) run rate and $30.8m contracted ARR, both slightly below the Wilsons' forecasts, while operating cash flow of $2.6m marked the second consecutive positive quarter.

Total contract value for the quarter was $5.1m, driven primarily by renewals, with no new customer wins reported, observes the broker.

Management reiterated FY25 guidance of 15-25% year-on-year growth in ARR and contracted ARR, though fourth-quarter wins are required to meet targets, cautions the analyst.

Veterans Affairs implementation, once expected in mid-2024, may now slip to FY26, reducing the broker's FY26 and FY27 forecasts.

Wilsons lowers the target price to 85c from $1.00 and retains an Overweight rating.

FORECAST
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Extra Coverage Research History >

M7T STOCK CHART

FNArena News on M7T

1
FNArena Corporate Results Monitor – 28-08-2025

Aug 28 2025 - Australia
2
Australian Broker Call *Extra* Edition – May 01, 2025

May 01 2025 - Daily Market Reports
3
FNArena Corporate Results Monitor – 28-02-2025

Feb 28 2025 - Australia
4
Rudi’s View: Best Buys & Convictions For 2025

Jan 16 2025 - Rudi's View
5
Rudi’s View: Final Best Buys & Conviction Ideas

Dec 23 2024 - Rudi's View

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps